UY27455A1 - Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. - Google Patents

Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.

Info

Publication number
UY27455A1
UY27455A1 UY27455A UY27455A UY27455A1 UY 27455 A1 UY27455 A1 UY 27455A1 UY 27455 A UY27455 A UY 27455A UY 27455 A UY27455 A UY 27455A UY 27455 A1 UY27455 A1 UY 27455A1
Authority
UY
Uruguay
Prior art keywords
derivatives
ciclopentapirazol
tetrahidro
drugs
replaced
Prior art date
Application number
UY27455A
Other languages
English (en)
Inventor
Alexander Ernst
Martin Kruger
Martin Haberey
Olaf Prien
Gerhard Siemeister
Andreas Steinmeyer
Jorg Kroll
Jens Hoffmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27455A1 publication Critical patent/UY27455A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen derivados N- (1,4,5,6-tetrahidro- ciclopen-tapirazol-3-il) sustituidos, su preparación, así como productos semielaborados para su preparación y el uso como fármaco para el tratamiento de diferentes enfermedades.
UY27455A 2001-09-25 2002-09-25 Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. UY27455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10148618A DE10148618B4 (de) 2001-09-25 2001-09-25 Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UY27455A1 true UY27455A1 (es) 2003-04-30

Family

ID=7701135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27455A UY27455A1 (es) 2001-09-25 2002-09-25 Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.

Country Status (5)

Country Link
US (2) US6747046B2 (es)
DE (1) DE10148618B4 (es)
PE (1) PE20030447A1 (es)
UY (1) UY27455A1 (es)
WO (1) WO2003029223A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
KR20150029766A (ko) 2005-02-25 2015-03-18 에사넥스, 인코포레이티드 테트라히드로인돌론 및 테트라히드로인다졸론 유도체
BRPI0613429A2 (pt) 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928847A4 (en) * 2005-08-29 2011-08-10 Gerard M Housey THERAMUTEINE MODULATORS
US20070185184A1 (en) * 2005-09-16 2007-08-09 Serenex, Inc. Carbazole derivatives
CA2623803A1 (en) * 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007101156A1 (en) * 2006-02-27 2007-09-07 Serenex, Inc. Cyclohexylamino, benzene, pyridine, and pyridazine derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080119457A1 (en) * 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
LT3302448T (lt) * 2015-06-04 2024-02-12 Aurigene Oncology Limited Pakeisti heterociklilo dariniai kaip cdk inhibitoriai
RS65621B1 (sr) 2018-04-18 2024-07-31 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, sastavi i njihova upotreba
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
GB9911053D0 (en) * 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE60023012T2 (de) * 1999-08-12 2006-07-20 Pharmacia Italia S.P.A. 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses

Also Published As

Publication number Publication date
PE20030447A1 (es) 2003-07-03
DE10148618B4 (de) 2007-05-03
US20040186156A1 (en) 2004-09-23
US20030212121A1 (en) 2003-11-13
WO2003029223A1 (de) 2003-04-10
US6747046B2 (en) 2004-06-08
DE10148618A1 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
DOP2002000429A (es) Imidazotriazinas
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
HN2003000196A (es) Derivados de indolinfenilsulfonamida
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AR037109A1 (es) Uso de flibanserina
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
PA8551001A1 (es) Nuevos compuestos
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
UY28313A1 (es) Nonadepsipeptidos acilados
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126